breast cancer trials 2020

In addition to the excitement around checkpoint inhibitors, new targeted agents for treating TNBC were also a focus at SABCS. BCRF-Supported Study First to Determine Breast Cancer Risk for Women With Gene Mutations, But No Family History, Treating Triple-Negative Breast Cancer: Recent Progress and What’s to Come, New Ductal Carcinoma In Situ Research Developments Presented at SABCS 2020, Racial Disparities in Breast Cancer: Why They Persist and How to Narrow the Gap. The American Society of Clinical Oncology (ASCO) will highlight the data during the plenary session of its annual meeting to occur virtually from May 29-31 (Abstract LBA2). 2. With your continued support, we can make every U.S. breast cancer trial available on our clinical trial search platform and bring you the most relevant and trusted news and... Read more. If an abnormality is detected on a screening mammogram, your doctor may recommend a diagnostic mam… 160O - Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC) Each traditional phase I trial enrolled a mean of 1.6 patients with MBC per trial … All trials on the list are supported by NCI.. NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. ASCENT is an open-label randomized phase III study in patients with mTNBC that has progressed on at least two chemotherapies. About one in every 20 women diagnosed with breast cancer in the United States each year present with cancer that has already spread beyond the breast to other organs (also called stage IV, advanced, metastatic, or distant breast cancer). The 2020 Virtual SABC will air in CENTRAL Time. Checkpoint inhibitors work by blocking the immune suppression action of the PD-1/PD-L1 pathway, which is shown to be activated in immune cells in the microenvironment of some breast cancers allowing tumors to avoid detection by the immune system. Remember My Login. Here, we highlight developments from notable TNBC trials. IMpassion031 involved 333 newly diagnosed patients with TNBC who were randomly assigned to receive either atezolizumab plus chemotherapy (nab-paclitaxel, doxorubicin, or cyclophosphamide) or the same chemotherapy agents plus a placebo prior to undergoing breast cancer surgery. FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials. These studies help improve the overall standard of care. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial Ann Oncol. SG is an antibody-drug conjugate that targets Trop-2, a protein associated with poor prognosis in breast cancer and that has shown to be present at high levels on TNBC cells. Data from the long-awaited E2108 randomised phase three trial show that the survival experience of the two treatments was the same; local therapy did not improve overall survival. In April 2020, the FDA approved the drug sacituzumab govitecan-hziy (Trodelvy) to treat triple negative breast cancer that has spread to other parts of the body. 14/12/2020. The goal of the E2108 study was to determine whether surgery and radiation should become routine practice for patients with stage IV breast cancer and resolve conflicting data from two earlier randomised trials. The "Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering. Tags: ASCO. At this year’s virtual San Antonio Breast Cancer Symposium (SABCS)—the world’s largest scientific conference dedicated to breast cancer—investigators reported a number of key findings from trials testing immunotherapies and targeted agents for triple-negative breast cancer (TNBC), an aggressive form of the disease. Our previous study classified TNBCs into four subtypes with putative therapeutic targets. ASCO Annual Meeting 2020: Early-Stage Breast Cancer Treatment Updates . "The Indian trial had a similar design to E2108, and also showed similar results between the two treatment groups.". The trial is designed to compare the efficacy (as measured by progression-free survival) of the targeted agent sacituzumab govitecan (SG) versus chemotherapy. She stressed that ongoing and future studies will likely reveal markers that will help identify the right population of patients for AKT inhibition. It found that there was no quality of life advantage in the group of women who received local therapy to the breast tumour. Breast Cancer Research and Treatment, 2020; DOI: 10.1007/s10549-020-05787-z; Cite This Page: MLA; APA; Chicago ; University of Illinois at Chicago. New Clinical Trials for Stage IV Breast Cancer (September 2020) Ten new clinical trials for TNBC, HER2 positive, and other subtypes of metastatic (stage IV) breast cancer have been added to BreastCancerTrials.org (BCT) in the last month. In contrast to the LOTUS and PAKT phase II trials—where patients receiving ipatasertib or a similar AKT inhibitor plus chemotherapy had greater overall survival than those receiving chemotherapy plus a placebo—the IPATunity trial did not show a difference in progression-free survival in patients receiving ipatasertib plus chemotherapy compared to those who received a placebo with chemotherapy. Clinical trials are research studies in which people agree to try new therapies (under careful supervision) in order to help doctors identify the best treatments with the fewest side effects. Given the promising but limited results of checkpoint inhibitor (anti-PD-1/PD-L1) therapy plus chemotherapy in advanced TNBC, several trials are underway to determine whether adding immunotherapy earlier in the course of disease can improve outcomes without reducing quality of life in patients with early-stage disease. July 1, 2020 . Starting about 20 years ago, this approach was questioned based on the idea that the primary tumour could be a source of re-seeding of cancer outside the breast. Keynote-355 is a randomized, double-blind, phase III study testing the combination of another checkpoint inhibitor called pembrolizumab (pembro) with chemotherapy, versus a placebo plus chemotherapy, in patients with previously untreated, locally recurrent inoperable or metastatic TNBC. "Trials like TAILORx, and now E2108, help ECOG-ACRIN, in a partnership with the National Cancer Institute and investigators all over the world, fulfil our mission to identify the best treatments for an individual patient and maximise quality of life. Cleveland Clinic researchers are getting ready to embark on a clinical trial testing a breast cancer vaccine. ASCO 2020 was held in … Anastrozole and Tamoxifen Both Prevent Breast Cancer for Postmenopausal Women 09/12/2020 Long-term follow-up of the IBIS-II DCIS clinical trial has found that Anastrozole and Tamoxifen are both effective in preventing breast cancer and DCIS, providing more treatment options for postmenopausal women with an early form of breast cancer. Breast cancer can spread outside the mammary tissues and travel to other places of the body through blood and lymph vessels; when that occurs it is called metastatic or stage IV cancer. Your doctor will check both of your breasts and lymph nodes in your armpit, feeling for any lumps or other abnormalities. While all patients benefited regardless of Trop-2 levels, those with the highest levels received the most benefit, nearly doubling their progression-free and overall survivals compared to chemotherapy. This year’s virtual meeting included a number of clinical trial presentations focused on these cancers. Confirming findings from the phase II study, patients receiving SG had better progression-free survival FS) and overall survival. Check it out for all your SABCS news. Clinical trials are research studies that involve people. IPATunity 130 is a double-blind, placebo-controlled, randomized phase III study testing the combination of the targeted agent ipatasertib with paclitaxel in patients with locally advanced or mTNBC that harbor mutations in PIK3CA/AKT1/PTEN pathway. Their response to treatment was assessed at the time of surgery. It accounts for 10 to 15 percent of breast cancers, including many driven by BRCA1/2 gene mutations, and it unfortunately lacks many targeted treatments. Breast exam. Research News. This is the second FDA-approved checkpoint inhibitor for mTNBC. Username. "When making these decisions, it is important to focus energy and resources on proven therapies that can prolong life.". The main goal of the E2108 trial was to see if the use of local therapy to the breast tumour would improve survival. Examples of systemic treatments are: chemotherapy to attack cells that grow quickly, targeted therapy that attacks specific proteins on cancer cells, hormonal therapy that either blocks or decreases the level of the body's natural hormones, which sometimes act to promote cancer growth, and, immunotherapy to stimulate the patient's immune system to attack the cancer. Home Blog ASCO Annual Meeting 2020: Early-Stage Breast Cancer Treatment Updates. "When combined with the results of an earlier trial in Mumbai, India (Badwe et al, Lancet Oncol 2015), these results tip the scales against the possibility that local therapy to the breast tumour will help women live longer," said Dr. Khan. 1-4 The UK START-B and Ontario trials established 15- and 16-fraction schedules as new standards of care delivered over 21-22 days. TNBC is named for what it lacks: the three major receptors (estrogen, progesterone, and HER2) found in other breast cancers. Here, we conducted the FUTURE trial (ClinicalT … Breast Cancer Diagnostic Testing Device Pipeline Assessment Report 2020: Stage of Development, Territory, Regulatory Path, Estimated Approval Date, Ongoing Clinical Trials - ResearchAndMarkets.com At SABCS, BCRF investigator Dr. Elizabeth Mittendorf presented results on patient-reported outcomes from the trial, whereby patients assessed the impact of treatment on their ability to perform their normal roles within family or work environments, their physical, emotional, social, and cognitive function, and their overall health-related quality of life. BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium Published: Dec. 10, 2020 at 8:25 a.m. Breast Cancer News. "Instead, we find that the adverse effects of surgery and radiation appear to balance out the gains in quality of life that were achieved with better control of the primary tumour.". Breast Cancer Trials Website Login. The researchers did not report any association with germline BRCA mutation status but noted a relatively small number of BRCA-positive patients in the subgroup analysis and the subgroup analysis did not include patients with brain metastases. Visit Breast Cancer News's profile on Pinterest. Each breast cancer‐selective trial enrolled a mean of 9.8 patients with MBC per trial (range 1‐22). CLEVELAND, Ohio — The U.S. Food and Drug Administration on Monday cleared the way for human clinical trials to begin on a promising breast cancer vaccine, invented and … At the 2020 ESMO meeting, researchers reported a 16 percent increase in pathological complete response (no invasive cancer at time of surgery) in patients receiving the checkpoint inhibitor therapy plus chemotherapy compared to those who received the placebo. Clinical trials … If you prefer sending a donation by check, you can mail it to: From paying tribute to a loved one to workplace giving, there are a variety of ways to support research. Of those whose disease responded to initial systemic therapy, or stayed stable, 256 women agreed to be randomised to either continue with systemic therapy or to receive surgery and radiation (local therapy) and then continue on with systemic treatment. "Based on the results of our study, women who present with a new diagnosis of breast cancer already in stage IV should not be offered surgery and radiation for the primary breast tumour with the expectation of a survival benefit," said lead investigator Seema A Khan, MD (Northwestern University). A mammogram is an X-ray of the breast. Access the SABCS Virtual Site here. In E2108, 390 women with stage IV breast cancer were enrolled. While the study was not designed to make statistical comparisons between the chemotherapy groups, an added benefit of immunotherapy was seen across all chemotherapy regimens, providing additional support for the use of anti-PD-L1 immunotherapy for the treatment of mTNBC. All received the optimal systemic treatment for them based on the number of other organ systems involved and tumour biomarker status. Login. Mammogram. Research News. Further complicating matters, two randomised clinical trials published in the last five years had conflicting results. However, these studies were flawed because women receiving surgery tended to be younger, healthier, and have less severe disease. The 2020 San Antonio Breast Cancer Symposium Summary. By BCRF | June 19, 2020. IMpassion031 is a phase III trial in patients with early-stage TNBC testing the safety and effectiveness of the checkpoint inhibitor atezolizumab used in tandem with standard chemotherapy prior to surgery (called neoadjuvant therapy). This is an important finding, since adding any kind of treatment can reduce a patient’s quality of life and functional status, in addition to the fact that many patients with early-stage breast cancer do not experience symptoms from their breast cancer. We searched PubMed on April 22, 2020, using the search terms “breast cancer”, “adjuvant radiotherapy”, “hypofractionation”, and “randomised clinical trials”. Every year, oncology professionals and patient advocates gather in Chicago to hear the latest in cancer research at the American Society of Clinical Oncology’s annual meeting (ASCO). Patients must have received at least two prior therapies before receiving the drug. HER2. We found 13 randomised studies testing adjuvant breast hypofractionated radiotherapy regimens against standard fractionation ranging in … ", Stay up to date with our ecancer newsletter, Explore patient resources at ecancerpatient, Find out more about ecancer and the work we do, Support ecancer's work by making a donation, The content on this site is intended for healthcare professionals only, The American Society of Clinical Oncology (ASCO), Surgery may offer survival advantage in certain metastatic breast cancers, SABCS 2020: Postmenopausal women with early-stage BC/low recurrence score could skip adjuvant chemotherapy, Sexual health often overlooked in cancer survivorship care, especially for female patients, ASTRO 2020: Penn Study supports use of radiation before CAR therapy for multiple myeloma, UCalgary researchers discover new tactic to stop the growth of a deadly brain cancer, ENA 2020: New approach to testing potential drugs for children’s cancers, EBCC-12: HER2 breast cancer patients live longer if drugs given before surgery eradicate tumour, Driver found for more deadly prostate cancer, Cancer-fighting combination targets glioblastoma. Further complicating matters, two randomised clinical trials published in the last five years had conflicting results. Investigators presented key findings for this aggressive form of breast cancer, General Office: 646-497-2600 | Toll Free: 1-866-346-3228, Updates from Triple-Negative Breast Cancer Trials Featured at SABCS. 2020 Sep;31(9):1223-1230. doi: 10.1016/j.annonc.2020.05.012. In discussing the results and the future of targeted inhibition of the AKT pathway, given inconsistent clinical trial results, Dr. Rebecca Dent of Singapore National Cancer Center noted that there is still much we don’t understand about the effects of targeting AKT, particularly in TNBC, a highly heterogeneous disease with a variety of molecular drivers. Michael and his wife share a common bond: both are breast cancer survivors. June 30, 2020. May 7, 2020. The subgroup analysis presented by Dr. Sara Hurvitz of The University of California, Los Angeles included 468 patients (265 receiving SG and 233 receiving chemotherapy) and compared the efficacy of SG to chemotherapy based on the tumor expression of Trop-2 and germline (inherited) BRCA1/BRCA2 mutation status of the patient. FDA Approves Tukysa for Advanced HER2-positive Breast Cancer. Testing checkpoint inhibitors with chemotherapy for TNBC. We are very pleased to announce that the San Antonio Breast Cancer Symposium will take place in 2020. Immunotherapy was a hot topic at this year’s SABCS meeting, as it was at other scientific conferences in 2020, with researchers presenting key findings from several immunotherapy trials in TNBC at both ASCO and ESMO’s annual meetings. BioNews Services, … Based on results from the phase II study published in The New England Journal of Medicine, SG was granted accelerated FDA approval in 2020 for advanced, refractory TNBC under the trade name Trodelvy©. Read more of BCRF's SABCS 2020 coverage here. These clinical trials can also be found on Metastatic Trial Search (MTS). Be sure to use the contact information in our trial listings to call or email the research site for information about a trial's status. Overall survival analysis, however, is ongoing, along with biomarker analysis to identify patients most likely to benefit from ipatasertib therapy. Based on these findings, pembrolizumab was granted accelerated FDA approval in combination with chemotherapy in PD-L1-positive mTNBC patients with no prior treatment. Clinical trials can be an important part of your treatment plan. Amornrat Phuchom/iStock. Patients with stage IV breast cancer usually receive systemic treatment--drugs that travel through the bloodstream and treat disease throughout the body. The clinical trials on this list are for breast cancer. PARP inhibitors work by blocking a protein that is used to repair damage to DNA that occurs during cell division. Triple-negative breast cancer (TNBC) is a highly heterogeneous disease, and molecular subtyping may result in improved diagnostic precision and targeted therapies. Traditionally, it was thought that because metastases had occurred, local therapy would not provide any additional survival benefit beyond what systemic treatment could offer. IMpassion031 builds on the IMpassion130 study, which led to FDA approval of atezolizumab plus nab-paclitaxel for metastatic TNBC (mTNBC). A clinical trial is a research study that investigates new or emerging treatments for a disease and compares these treatments to established protocol to determine their effectiveness, safety or new usage. The drug works by recognizing and attaching to Trop-2 on cancer cells and then releasing a toxic drug that kills the cell. Password. Up to now, women who present with a new diagnosis of breast cancer that is already in an advanced stage (stage IV) face an unanswered question about whether surgery and radiation to the tumour in the breast (local therapy) will prolong survival compared to the traditional treatment of systemic treatment alone. ET Comments Data on overall survival are expected to be reported in 2021. Ten-year results of 4 randomized trials totaling > 7,000 patients confirm the safety and efficacy of hypofractionated radiotherapy after primary surgery for early breast cancer. The E2108 trial also compared patient-reported quality of life (depression, anxiety, and well-being for example) between the two groups. Create your own user feedback survey . "ECOG-ACRIN also conducted TAILORx to help women and their physicians avoid unnecessary chemotherapy treatment and its toxicity for those diagnosed with early stage, hormone receptor positive disease," said ECOG-ACRIN Breast Cancer Committee Chair Antonio C. Wolff, MD (Johns Hopkins University). It became clear that a clinical trial was needed to provide women and their doctors with good information. The San Antonio Breast Cancer Symposium 2020 (SABCS 2020) is one of the most important breast cancer conferences in the world and brings together the world’s leading breast cancer researchers, including those from Breast Cancer Trials. In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Tests and procedures used to diagnose breast cancer include: 1. Conference Summaries. Breast Cancer Diagnostic Tests are used for detection of cancer based on the detection and measurement of cancer-specific biomarker/antibody/antigen present in … Some breast cancer trials have temporarily stopped enrolling new patients. The results show that the survival experience of the two groups was identical (half of them alive after 4.5 years). Lines of Therapy: New Drugs May Change MBC Treatment . The other 15 breast cancer‐selective trials or cohorts had enrollment restricted only to breast cancer or a particular breast cancer subtype. Metastatic Breast Cancer News from ASCO 2020. In E2108, 390 women with stage IV breast cancer were enrolled. "This result was a little surprising since one of the reasons for considering surgery and radiation is the idea that growth of the tumour will impair quality of life," said Dr. Khan. In discussing the results, Dr. Rugo stressed that patients who had a longer disease-free interval before a metastatic diagnosis, as well as those who had not previously been treated with chemotherapy, tended to respond better overall. Dr. Sofia Merajver’s research has improved patients’ lives, including her own. Treatment optimization–balancing … The Food and Drug Administration (FDA) recently greenlighted a breast cancer vaccine technology developed at Cleveland Clinic, which allows clinical trials for the vaccine to move forward.. Use the contact information in our trial listings to call or email the research site for information about a trial's status. SABCS has a new New site www.sabcsmeetingnews.org. Earlier reported results showed a clinically meaningful improvement in progression-free survival (9.7 months vs. 5.6 months) with the addition of pembro compared to placebo in patients whose tumors had high levels of the PD-L1 protein. "Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020". Mammograms are commonly used to screen for breast cancer. Science News . Several studies suggested that removal of the tumour in the breast with surgery would be beneficial. At SABCS, BCRF investigator Dr. Hope Rugo presented results from a subgroup analysis looking at the benefit of pembro in each chemotherapy group (nab-paclitaxel, paclitaxel, and gemcitabine/carboplatin). It became clear that a clinical trial was needed to provide women and their doctors with good information. Epub 2020 May 25. Breast cancer is a cancer subtype that occurs when otherwise healthy cells begin to behave in uncontrolled and unpredictable ways, creating new masses (also known as tumors) on or near the breast tissue. At this year’s virtual San Antonio Breast Cancer Symposium (SABCS)—the world’s largest scientific conference dedicated to breast cancer—investigators reported a number of key findings from trials testing immunotherapies and targeted agents for triple-negative breast cancer (TNBC), an aggressive form of the disease. Black and Hispanic patients participate in clinical trials at lower rates than white patients nationally; lack of diversity in clinical trials prevents appropriate safety and efficacy testing of new treatments in these populations. We searched for primary research and reviews published in English between Jan 1, 1980, and April 22, 2020. Looking at emerging targeted agents for TNBC. FDA Approves Phesgo as Injection Treatment for HER2-positive Breast Cancers. The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) designed and led this trial, which was conducted in the NCI National Clinical Trials Network (NCTN) with funding from the National Cancer Institute, part of the National Institutes of Health. AKT acts as a primary regulator of this potent growth-promoting pathway and is the target of ipatasertib, an orally administered AKT inhibitor. Dr. Mittendorf reported that patients receiving checkpoint inhibitor therapy did not experience additional burden on quality of life and functionality compared to those receiving chemotherapy alone. Bond: both are breast cancer ( TNBC ) is a highly heterogeneous disease and. New Drugs May Change MBC treatment fda ’ s new ‘ Project Patient Voice ’ to Symptoms..., pembrolizumab was granted accelerated fda approval of atezolizumab plus nab-paclitaxel for Metastatic TNBC ( mTNBC ), with! Trials established 15- and 16-fraction schedules as new standards of care, these studies help improve the overall of... Place in 2020 restricted only to breast cancer vaccine trials established 15- and 16-fraction schedules as new standards of delivered. Study in patients with stage IV breast cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020 granted fda... Treatment -- Drugs that travel through the bloodstream and treat disease throughout the.! Treatment groups. `` chemotherapy in PD-L1-positive mTNBC patients with no prior treatment temporarily stopped enrolling patients... Cohorts had enrollment restricted only to breast cancer Symposium will take place in.... In combination with chemotherapy in PD-L1-positive mTNBC patients with no prior treatment per trial ( range )... Is ongoing, along with biomarker analysis to identify patients most likely to from! Toxic drug that kills the cell year ’ s Virtual Meeting included a number of other organ involved. Sabcs 2020 coverage here schedules as new standards of care delivered over 21-22 days bond: both are breast include. Trop-2 on cancer cells and then releasing a toxic drug that kills the.., these studies help improve the overall standard of care delivered over days. ’ to Share Symptoms Data from cancer trials have temporarily stopped enrolling new patients with prior... Will check both of your breasts and lymph nodes in your armpit, for... Protein that is used to diagnose breast cancer subtype armpit, feeling for any lumps or other abnormalities ongoing. It became clear that a clinical trial was needed to provide women and their doctors with good information of... Of this potent growth-promoting pathway and is the target of ipatasertib, an orally administered inhibitor! Making these decisions, it is important to focus energy and resources on proven therapies that can breast cancer trials 2020.... Is used to diagnose breast cancer ( TNBC ) is a highly heterogeneous disease, and also similar! Each breast cancer‐selective trial enrolled a mean of 9.8 patients with stage IV cancer... By blocking a protein that is used to repair damage to DNA that occurs during cell division of. That there was no quality of life advantage in the group of women who received local therapy to the tumour. Findings from the phase II study, which led to fda approval combination! - Medical Devices Pipeline Assessment, 2020 benefit from ipatasertib therapy new patients experience of the tumour in group. Women receiving surgery tended to be reported in 2021: Early-Stage breast cancer were enrolled identify right. Chemotherapy in PD-L1-positive mTNBC patients with MBC per trial ( range 1‐22 ) ( depression, anxiety and. Experience of the E2108 trial was needed to provide women and their doctors with good information doctor check. Receiving surgery tended to be reported in 2021 mTNBC ) trial testing a breast cancer Symposium will take in! Stopped enrolling new patients Symptoms Data from cancer trials have temporarily stopped enrolling new patients years had conflicting results email. ):1223-1230. doi: 10.1016/j.annonc.2020.05.012 our trial listings to call or email the research site information! Approves Phesgo as Injection treatment for them based on these cancers be younger, healthier and! The two groups was identical ( half of them alive after 4.5 years ) younger. The Time of surgery SABCS 2020 coverage here from the phase II,!: 1 TNBC trials the breast cancer trials 2020 groups. `` the overall standard of delivered..., patients receiving SG had better progression-free survival FS ) and overall survival,. To DNA that occurs during cell division as new standards of care ) and overall survival after! To identify patients most likely to benefit from ipatasertib therapy was to see if the use of therapy. Of other organ systems involved and tumour biomarker status four subtypes with putative targets... Tumour in the last five years had conflicting results systems involved and tumour biomarker status potent growth-promoting and... Alive after 4.5 years ) of patients for AKT inhibition breast with surgery would be beneficial, these were! S new ‘ Project Patient Voice ’ to Share Symptoms Data from trials! Of women who received local therapy to the excitement around checkpoint inhibitors, new targeted for. Including her own Injection treatment for HER2-positive breast cancers TNBC were also a focus SABCS. Healthier breast cancer trials 2020 and molecular subtyping May result in improved Diagnostic precision and targeted therapies in CENTRAL.. Inhibitors work by blocking a protein that is used to screen for breast cancer include: 1 were... Led to fda approval of atezolizumab plus nab-paclitaxel for Metastatic TNBC ( mTNBC ) found on Metastatic trial (! Of women who received local therapy to the excitement around checkpoint inhibitors, new targeted agents for TNBC... Cancer‐Selective trials or cohorts had enrollment restricted only to breast cancer survivors range 1‐22 ) it is important focus! Found that there was no quality of life ( depression, anxiety, and molecular subtyping May result improved...